Europe Human Microbiome Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143352
- Pages: 225
-
Format:
Short Description
Europe Human Microbiome Market, By Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Supplements, Fecal Microbiota Transplant, and Others), Application (Therapeutic and Diagnostic), Disease (Infectious Disease, Dermatological Disorders, Autoimmune Disorder, Metabolic Disorder, Gastrointestinal Disorders, Cancer, Mental Disorders, Clostridioides Difficile Infection, Primary Hyperoxyureasolution-Phase, and Others), Technology (Genomics, Proteomics, and Metabolomics), Type (Small Molecule and Biologic), End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Hypermarket/Supermarket, Clinics, and Others), Distributor (Direct Tender and Retail Sales), Country (Germany, U.K., France, Italy, and Spain) Industry Trends and Forecast to 2029
Market Definition
Microbiota means the microbial taxa associated with humans, and microbiome means the catalog of these microbes and their genes. The aggregation of all the microbiota reside on or within human tissues and bio fluids along with corresponding anatomical sites, including the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and others. The human microbiota consists of the 10-100 trillion symbiotic microbial cells harbored by each person, primarily bacteria in the gut. The human microbiome consists of the genes these cells harbor.
The microbiome is the genetic material of all the microbes - bacteria, fungi, protozoa, and viruses - that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome. The most widely used method of identification of microbiome analysis is 16s rRNA sequencing. Identification and understanding of these microbiotas have led to the application of these microorganisms in the betterment of human health via various products such as probiotics, prebiotics, and other associated drugs
Market Segmentation
Europe human microbiome market is categorized into seven notable segments based on product, application, disease, technology, type, end user, and distributor. In 2022, product segment is expected to dominate the market due to rise in incidence and prevalence of lifestyle disorders and chronic diseases.
On the basis of product, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs, supplements, fecal microbiota transplant, and others
On the basis of application, the market is segmented into therapeutic and diagnostic
On the basis of disease, the market is segmented into infectious disease, dermatological disorders, autoimmune disorder, metabolic disorder, gastrointestinal disorders, cancer, mental disorders, C. Difficile infection, primary hyperoxyureasolution-phase, and others
On the basis of technology, the market is segmented into genomics, proteomics and metabolomics
On the basis of type, the market is segmented into small molecule and biologic
On the basis of end user, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, hypermarket/supermarket, clinics, and others
On the basis of distributor, the market is segmented into direct tender and retail sales
Market Players
The key market players for Europe human microbiome market are listed below:
YSOPIA Bioscience
Evelo Biosciences, Inc.
OptiBiotix HEALTH PLC
Atlas Biomed Group Limited
LUXIA SCIENTIFIC
Ferring B.V.
Merck KGaA
Assembly Biosciences, Inc.
Synthetic Biologics, Inc
Enterome
OxThera
Gnubiotics Sciences
Embion Technologies S.A.
TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF EUROPE HUMAN MICROBIOME MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 34
2.7 PRODUCT LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET APPLICATION COVERAGE GRID 38
2.11 VENDOR SHARE ANALYSIS 39
2.12 SECONDARY SOURCES 40
2.13 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 44
4.1 PESTEL 46
4.2 PORTER'S FIVE FORCES MODEL 47
4.3 GLOBAL HUMAN MICROBIOME MARKET ANALYSIS 48
4.4 GUT MICROBIOME AND DIAGNOSTIC 49
5 EPIDEMIOLOGY 50
5.1 EPIDEMIOLOGY CANCER 50
5.2 EPIDEMIOLOGY DERMATOLOGICAL DISORDERS 51
5.3 EPIDEMIOLOGY GASTRIC DISORDERS 52
5.4 EPIDEMIOLOGY IMMUNE DISORDERS 53
5.5 EPIDEMIOLOGY METABOLIC DISORDERS 54
6 INDUSTRY INSIGHTS 55
6.1 DEMOGRAPHIC TRENDS 55
6.2 KEY PRICING STRATEGIES 55
7 INDUSTRY INSIGHT 56
7.1 PATENT ANALYSIS 56
7.2 PATENT FLOW DIAGRAM 57
8 REGULATORY FRAMEWORKS 58
8.1 UNITED STATES 58
8.2 EUROPE 59
9 MARKET OVERVIEW 61
9.1 DRIVERS 63
9.1.1 RISING PREVALENCE OF LIFESTYLE AND CHRONIC DISEASES 63
9.1.2 HUMAN MICROBIOME THERAPEUTIC DEVELOPMENT FOR DISEASE TREATMENT 63
9.1.3 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING 64
9.2 RESTRAINTS 64
9.2.1 BARRIERS PROVING THE CAUSAL LINK BETWEEN DYSBIOSIS AND DISEASES 64
9.2.2 LACK OF TECHNOLOGY EXPERTISE 65
9.3 OPPORTUNITIES 65
9.3.1 RISE IN HEALTHCARE EXPENDITURE 65
9.3.2 INCREASING RESEARCH AND DEVELOPMENT 66
9.4 CHALLENGE 67
9.4.1 RISK ASSOCIATED WITH HUMAN MICROBIOME PRODUCTS 67
10 EUROPE HUMAN MICROBIOME MARKET, BY PRODUCT 68
10.1 OVERVIEW 69
10.2 PROBIOTICS 71
10.2.1 BRANDED 72
10.2.1.1 OPTIPAC-PREBIOTICS FIBRE 72
10.2.1.2 ENZYMEDICA-PREBIOTICS DRINK MIX 72
10.2.1.3 SWEETBIOTIX 73
10.2.1.4 OTHERS 73
10.2.2 GENERICS 73
10.3 PREBIOTICS 73
10.3.1 BRANDED 74
10.3.1.1 BIOM PROBIOTIC 74
10.3.1.2 BIOM D FEND 74
10.3.1.3 FLORE GUT MICROBIOME TEST 75
10.3.1.4 REVITIFY 75
10.3.1.5 SYMBIOTIC YOGURT 75
10.3.1.6 SYMBIOTIC 75
10.3.1.7 LPLDL 75
10.3.1.8 LPGOS 75
10.3.1.9 OTHERS 75
10.3.2 GENERICS 76
10.4 SUPPLEMENTS 76
10.4.1 CHOLBIOME 77
10.4.2 LPGOS 77
10.4.3 WELL BIOME 77
10.4.4 FLORE BOOM 77
10.4.5 FLORE DEFENCE 77
10.4.6 FLORE BALANCE 77
10.4.7 BIOM 77
10.4.8 REVITIFY 78
10.4.9 FLORE 78
10.4.10 BIOM D FEND 78
10.4.11 SLIM BIOME 78
10.4.12 OTHERS 78
10.5 DIAGNOSTICS TESTS 78
10.5.1 FLORE GUT MICROBIOME TEST 79
10.5.2 FLORE 360 79
10.5.3 BIOME MICROBIOME TEST 79
10.5.4 SUPER GUT MICROBIOME HEALTH TEST 80
10.5.5 HEALTH INTELLIGENCE TEST 80
10.5.6 GUT INTELLIGENCE TEST 80
10.5.7 X MARKER 80
10.5.8 ATLAS MICROBIOME TEST 80
10.5.9 1TEST 1 80
10.5.10 LIFE KIT 80
10.5.11 FOR A 81
10.5.12 OTHERS 81
10.6 DRUGS 81
10.6.1 OXABACT 82
10.6.2 SINTAX 82
10.6.3 SYNBIOTIC YOGURT 82
10.6.4 SYNBIOTIC 7 82
10.6.5 MICRORX 82
10.6.6 SLIM BIOME 82
10.6.7 SLIM BIOME MEDICAL 82
10.6.8 LPLDL 83
10.6.9 CHOLBIOME 83
10.6.10 OTHERS 83
10.7 FECAL MICROBIOTA TRANSPLANT 83
10.8 OTHERS 83
11 EUROPE HUMAN MICROBIOME MARKET, BY APPLICATION 85
11.1 OVERVIEW 86
11.2 THERAPEUTIC 89
11.2.1 SINGLE STRAIN OR MULTI-STRAIN CONSORTIA 89
11.2.2 LIQUID OR DRIED BULK DRUG SUBSTANCE 89
11.2.3 SOLID ORAL DOSE 90
11.2.4 OTHERS 90
11.3 DIAGNOSTIC 90
11.3.1 IRRITABLE BOWEL SYNDROME 91
11.3.2 LEAKY GUT SYNDROME 91
11.3.3 DIABETES 91
11.3.4 BACTERIAL VAGINOSIS 91
11.3.5 GINGITIVIS 91
11.3.6 TRICHOMONIASIS 92
11.3.7 VAGINAL CANDIDIASIS 92
12 EUROPE HUMAN MICROBIOME MARKET, BY DISEASE 93
12.1 OVERVIEW 94
12.2 INFECTIOUS DISEASE 97
12.2.1 HELICOBACTER PYLORI 97
12.2.2 C. DIFFICILE INFECTIONS 97
12.2.3 BACTERIAL VAGINOSIS 97
12.2.4 OTHERS 98
12.3 GASTROINTESTINAL DISORDERS 98
12.4 C. DIFFICILE INFECTION 98
12.5 METABOLIC DISORDER 99
12.5.1 DIABETES 99
12.5.2 OBESITY 99
12.5.3 ENDOCRINE 99
12.5.4 NON ALCOHOLIC LIVER DISEASE 100
12.6 AUTOIMMUNE DISORDER 100
12.7 CANCER 100
12.8 MENTAL DISORDER 101
12.9 DERMATOLOGICAL DISORDERS 101
12.9.1 ATOPIC DERMATITIS 101
12.9.2 ROSACEA 101
12.9.3 ACNE 102
12.9.4 OTHERS 102
12.10 PRIMARY HYPEROXYUREASOLUTION-PHASE 102
12.11 OTHERS 103
13 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY 104
13.1 OVERVIEW 105
13.2 GENOMICS 107
13.2.1 SEQUENCING 108
13.2.1.1 16S RRNA SEQUENCING METHOD 108
13.2.1.2 SHOTGUN METAGENOMICS SEQUENCING 109
13.2.1.3 WHOLE GENOME SEQUENCING 109
13.2.1.4 OTHER 109
13.2.2 POLYMERASE CHAIN REACTION 109
13.2.3 OTHER GENOMIC TECHNIQUES 109
13.2.4 ORGAN TRANSPLANTATION 109
13.2.5 OTHER CLINICAL APPLICATION 109
13.3 PROTEOMICS 110
13.3.1 EXPRESSION PROTEOMICS 110
13.3.2 FUNCTIONAL PROTEOMICS 110
13.3.3 STRUCTURAL PROTEOMICS 111
13.4 METABOLIMICS 111
13.4.1 TARGETED ANALYSIS 111
13.4.2 METABOLITE PROFILING 111
13.4.3 METABOLIC FINGERPRINTING 112
14 EUROPE HUMAN MICROBIOME MARKET, BY TYPE 113
14.1 OVERVIEW 114
14.2 SMALL MOLECULE 116
14.3 BIOLOGIC 117
15 EUROPE HUMAN MICROBIOME MARKET, BY END USER 118
15.1 OVERVIEW 119
15.2 ONLINE PHARMACIES 121
15.3 HYPERMARKET & SUPERMARKET 122
15.4 RETAIL PHARMACIES 122
15.5 HOSPITAL PHARMACIES 122
15.6 CLINICS 123
15.7 OTHERS 123
16 EUROPE HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL 124
16.1 OVERVIEW 125
16.2 RETAIL SALES 127
16.3 DIRECT TENDERS 128
17 EUROPE HUMAN MICROBIOME MARKET, BY COUNTRY 129
17.1 EUROPE 129
17.1.1 GERMANY 135
17.1.2 FRANCE 143
17.1.3 U.K. 151
17.1.4 ITALY 159
17.1.5 SPAIN 167
18 EUROPE HUMAN MICROBIOME MARKET: COMPANY LANDSCAPE 175
18.1 COMPANY SHARE ANALYSIS: EUROPE 175
19 COMPANY PROFILE 176
19.1 OPTIBIOTIX HEALTH PLC 176
19.1.1 COMPANY SNAPSHOT 176
19.1.2 PRODUCT PORTFOLIO 176
19.1.3 RECENT DEVELOPMENT 176
19.2 MERCK KGAA 177
19.2.1 COMPANY SNAPSHOT 177
19.2.2 PRODUCT PORTFOLIO 177
19.2.3 RECENT DEVELOPMENTS 177
19.3 FINCH THERAPEUTICS GROUP, INC 178
19.3.1 COMPANY SNAPSHOT 178
19.3.2 PIPELINE PRODUCT PORTFOLIO 178
19.3.3 RECENT DEVELOPMENT 178
19.4 FERRING B.V. 179
19.4.1 COMPANY SNAPSHOT 179
19.4.2 PIPELINE PRODUCT PORTFOLIO 179
19.4.3 RECENT DEVELOPMENTS 179
19.5 ATLAS BIOMED GROUP LIMITED 180
19.5.1 COMPANY SNAPSHOT 180
19.5.2 PRODUCT PORTFOLIO 180
19.5.3 RECENT DEVELOPMENTS 180
19.6 ENTEROME 181
19.6.1 COMPANY SNAPSHOT 181
19.6.2 PIPELINE PRODUCT PORTFOLIO 181
19.6.3 RECENT DEVELOPMENTS 181
19.7 ASSEMBLY BIOSCIENCES, INC. 183
19.7.1 COMPANY SNAPSHOT 183
19.7.2 PIPELINE PRODUCT PORTFOLIO 183
19.7.3 RECENT DEVELOPMENTS 183
19.8 BIOMX 185
19.8.1 COMPANY SNAPSHOT 185
19.8.2 PIPELINE PRODUCT PORTFOLIO 185
19.8.3 RECENT DEVELOPMENTS 185
19.9 EMBION TECHNOLOGIES S.A. 186
19.9.1 COMPANY SNAPSHOT 186
19.9.2 PIPELINE PRODUCT PORTFOLIO 186
19.9.3 RECENT DEVELOPMENTS 186
19.10 EVELO BIOSCIENCES, INC. 187
19.10.1 COMPANY SNAPSHOT 187
19.10.2 PIPELINE PRODUCT PORTFOLIO 187
19.10.3 RECENT DEVELOPMENTS 187
19.11 FLIGHTPATH BIOSCIENCES, INC. 188
19.11.1 COMPANY SNAPSHOT 188
19.11.2 PIPELINE PRODUCT PORTFOLIO 188
19.11.3 RECENT DEVELOPMENTS 188
19.12 GNUBIOTICS SCIENCES 189
19.12.1 COMPANY SNAPSHOT 189
19.12.2 PIPELINE PRODUCT PORTFOLIO 189
19.12.3 RECENT DEVELOPMENTS 189
19.13.1 COMPANY SNAPSHOT 191
19.13.2 PIPELINE PRODUCT PORTFOLIO 191
19.13.3 RECENT DEVELOPMENTS 191
19.14 LUXIA SCIENTIFIC 192
19.14.1 COMPANY SNAPSHOT 192
19.14.2 PRODUCT PORTFOLIO 192
19.14.3 RECENT DEVELOPMENTS 192
19.15 METABIOMICS 193
19.15.1 COMPANY SNAPSHOT 193
19.15.2 PRODUCT PORTFOLIO 193
19.15.3 RECENT DEVELOPMENTS 193
19.16 OSEL INC 194
19.16.1 COMPANY SNAPSHOT 194
19.16.2 PRODUCT PORTFOLIO 194
19.16.3 RECENT DEVELOPMENT 194
19.17 OXTHERA. 195
19.17.1 COMPANY SNAPSHOT 195
19.17.2 PIPELINE PRODUCT PORTFOLIO 195
19.17.3 RECENT DEVELOPMENTS 195
19.18 SECOND GENOME 197
19.18.1 COMPANY SNAPSHOT 197
19.18.2 PIPELINE PRODUCT PORTFOLIO 197
19.18.3 RECENT DEVELOPMENTS 197
19.19 SERES THERAPEUTICS 199
19.19.1 COMPANY SNAPSHOT 199
19.19.2 PIPELINE PRODUCT PORTFOLIO 199
19.19.3 RECENT DEVELOPMENTS 199
19.20 SUN GENOMICS 201
19.20.1 COMPANY SNAPSHOT 201
19.20.2 PRODUCT PORTFOLIO 201
19.20.3 RECENT DEVELOPMENTS 201
19.21 SYNTHETIC BIOLOGICS, INC.. 202
19.21.1 COMPANY SNAPSHOT 202
19.21.2 PIPELINE PRODUCT PORTFOLIO 202
19.21.3 RECENT DEVELOPMENTS 203
19.22 SYNLOGIC 204
19.22.1 COMPANY SNAPSHOT 204
19.22.2 PIPELINE PRODUCT PORTFOLIO 204
19.22.3 RECENT DEVELOPMENTS 205
19.23 VEDANTA BIOSCIENCES, INC. 206
19.23.1 COMPANY SNAPSHOT 206
19.23.2 PIPELINE PRODUCT PORTFOLIO 206
19.23.3 RECENT DEVELOPMENTS 206
19.24 VIOME LIFESCIENCES, US 208
19.24.1 COMPANY SNAPSHOT 208
19.24.2 PRODUCT PORTFOLIO 208
19.24.3 RECENT DEVELOPMENT 208
19.25 YSOPIA BIOSCIENCE 209
19.25.1 COMPANY SNAPSHOT 209
19.25.2 PIPELINE PRODUCT PORTFOLIO 209
19.25.3 RECENT DEVELOPMENT 209
19.26 4D PHARMA PLC 210
19.26.1 COMPANY SNAPSHOT 210
19.26.2 PRODUCT PORTFOLIO 210
19.26.3 RECENT DEVELOPMENTS 210
20 QUESTIONNAIRE 211
21 RELATED REPORTS 214
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
